Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder.

The treatment of acute agitation in psychiatric patients has traditionally involved the use of oral or intramuscular benzodiazepines, antipsychotics or their combination. However, oral medication may have too slow an onset and while the intramuscular route is faster, it carries an increased risk of adverse events and needle-stick injury. A new delivery modality has been devised using an inhalation-activated, thermally generated drug aerosol which can produce peak plasma concentrations in a few minutes. Using this delivery method, loxapine was assessed for its antiagitation effects in schizophrenia and bipolar I disorder patients. It produced a rapid calming effect without undue sedation. It was generally well tolerated, with dysgeusia being the most common adverse event.
AuthorsR T Owen
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 49 Issue 3 Pg. 195-201 (Mar 2013) ISSN: 1699-3993 [Print] United States
PMID23527323 (Publication Type: Journal Article)
CopyrightCopyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.
Chemical References
  • Antipsychotic Agents
  • Loxapine
  • Administration, Inhalation
  • Antipsychotic Agents (administration & dosage, pharmacokinetics, therapeutic use)
  • Bipolar Disorder (drug therapy, physiopathology)
  • Drug Delivery Systems
  • Humans
  • Loxapine (administration & dosage, pharmacokinetics, therapeutic use)
  • Psychomotor Agitation (drug therapy, etiology)
  • Schizophrenia (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: